Pharmaceutical Benefits Scheme – minor new listings

A number of drugs expected to cost less than $10 million a year each in subsidies, have been listed in the PBS. They include drugs for treatment of inflammatory arthritis, attention deficit hyperactivity disorder, autism and schizophrenia.

Page last updated: 08 May 2007

PDF printable version of Pharmaceutical Benefits Scheme – minor new listings (PDF 627 KB)

Why is this important?

  • These minor new listings are a mix of drugs that have been listed at an estimated cost each of less than $10 million a year.
  • The new listings include drugs for the treatment of inflammatory arthritis, attention deficit hyperactivity disorder, autism and schizophrenia.

Who will benefit?

  • It is estimated that approximately 84,000 people will start treatment in the first four years of listing. For some of these drugs, patients must meet specific criteria to be eligible for PBS-subsidised treatment.

What funding is the Government committing to the initiative?

  • The Government will provide funding of $78.9 million over five years.

What have we done in the past?

  • Expenditure on the PBS in 2005-06 was $6.2 billion.

When will the initiative conclude?

  • This initiative is ongoing.

In this section